CLAIMS:

1. A cell-free lipoaspirate-derived preparation **characterized** in that the preparation comprises at least one of a lipid fraction and an aqueous fraction of a lipoaspirate.

2. The cell-free preparation according to claim 1, wherein the aqueous fraction comprises spent liposuction solution, with or without a local anesthetic and/or adrenaline.

3. The cell-free preparation according to claim 1 or 2, wherein the preparation comprises the aqueous fraction of the lipoaspirate and the lipid fraction of the lipoaspirate as the only liposuction-derived material in the preparation.

4. The cell-free preparation according to claim 1 or 2, wherein the preparation comprises the aqueous fraction of the lipoaspirate, the lipid fraction of the lipoaspirate, and a spent liposuction solution not collected as part of the lipoaspirate as the only liposuction-derived material in the preparation.

5. The cell-free preparation according to any one of claims 1-4, which has been filtered through a membrane filter, preferably having a pore size of 0.2 μm or 0.22 μm.

6. The cell-free preparation according to any one of claims 1-5, wherein the preparation comprises one or more components selected from the group consisting of structural and non-structural extracellular matrix proteins, peptides, chains, subchains and subunits thereof; proteins related to the synthesis of extracellular matrix; lipids, lipid-associated proteins, proteins related to lipid metabolism; Basement membrane proteins peptides, chains, subchains and subunits thereof; specialized dermo-epidermal junction components and factors effecting epidermis; essential and non-essential amino acids; antioxidants; vitamin derivatives and metabolites; and glycoproteins and proteoglycans.

7. The cell-free preparation according to claim 6, wherein

i) said structural and non-structural extracellular matrix proteins, peptides, chains, subchains and subunits thereof include one or more component selected from the group consisting of Collagens I, III, IV, VI, XV, XVIII, fibronectin, vitronectin, elastin, hyaluronan, decorin, tenascin, laminin, lumican and prolargin; and/or

ii) said lipids, lipid-associated proteins, proteins related to lipid metabolism include one or more components selected from the group consisting of ceramids, apolipoproteins, perilipins, non-saturated and saturated fatty acids, glycerophospholipids, lysophosphatidic

acids, lysophospholipids, monoglycerides, diglycerides, triglycerides and prostaglandins; and/or

iii) said basement membrane and dermo-epidermal junction proteins, peptides, chains, subchains and subunits thereof include one or more component selected from the group consisting of keratin, nidogen, versican, intergrins, periplakin, plectin; and/or

iv) said vitamin derivates and metabolites include at least Tretinoin.

8. A method of producing the cell-free preparation according to any one of claims 1-7, comprising the steps of:
- providing a lipoaspirate obtained from at least one human subject;
- optionally, shaking the lipoaspirate;
- removing an adipose tissue fraction of the lipoaspirate, said fraction comprising cells; and
- filtering the remaining fractions of the lipoaspirate.

9. The method according to claim 8, wherein prior to removing the adipose tissue fraction, the lipoaspirate is allowed to such that the lipoaspirate separates into a lipid layer on the top, an adipose tissue layer comprising adipocytes and other cells of the adipose tissue in the middle, and an aqueous layer at the bottom.

10. A method of producing the cell-free preparation according to any ne of claims 1-7, comprising the steps of:
- providing a human lipoaspirate;
- optionally, shaking a human lipoaspirate;
- collecting at least one of a lipid fraction and an aqueous fraction, while discarding an adipose tissue fraction comprising cells; and
- filtering the collected fraction(s).

11. The method according to claim 10, wherein prior to collecting at least one of the lipid fraction and the aqueous fraction, the lipoaspirate is allowed to settle such that the lipoaspirate separates into a lipid layer on the top, an adipose tissue layer comprising adipocytes and other cells of the adipose tissue in the middle, and an aqueous layer at the bottom.

12. The method according to any one of claims 9-11, wherein the method does not include rinsing of the lipoaspirate or any fraction thereof.

13. The method according to any one claims 9-12, wherein the filtering is carried out by using a membrane filter having a pore size of 0.2 µm or 0.22 µm.

14. A cosmetic or pharmaceutical composition comprising the cell-free preparation according to any one of claims 1-7 and a physiologically acceptable carrier, adjuvant and/or excipient.

15. The cosmetic or pharmaceutical composition according to claim 14, wherein the composition is in the form of an ointment, lotion, cream, gel, hydrogel, oil-in-water emulsion, water-in-oil emulsion, drop, spray, liquid, solution, powder, slow release or sustained release formulation, face mask, skin patch, mousse or foam.

16. The cosmetic or pharmaceutical composition according to claim 14 or 15, wherein the composition is intended for topical administration, or for subcutaneous, intradermal or intrahypodermal administration.

17. Use of the cell-free preparation according to any one of claims 1-7 or the cosmetic composition according to any one of claims 14-16 for cosmetically treating the skin.

18. A non-therapeutic method for cosmetically treating the skin, the method comprising the step of applying the cell-free preparation according to any one of claims 1-7 or the cosmetic composition according to any one of claims 14-16 to the skin.

19. The use according to claim 17 or the method according to claim 18, wherein the skin is compromised skin, preferably prepared by microneedling, exfoliation and/or laser resurfacing.

20. The use according to claim 17 or the method according to claim 18, wherein the skin is aged skin or scarred skin.

21. Use of the cell-free preparation according to any one of claims 1–7 or the pharmaceutical composition according to any one of claims 14–16 in the manufacture of a medicament for treating a clinical skin condition.

22. The use according to claim 21, wherein the clinical skin condition is acne, actinic keratosis, atopic dermatitis, venous stasis dermatitis, eczema, basal cell carcinoma, contact dermatitis, keloids, lichen planus, melasma, vitiligo, psoriasis, rosacea, seborrheic dermatitis, chronic wounds such as diabetic wounds, burns, erythema multiforme, epidermolysis bullosa, lupus or keratosis pilaris.

23. Use of the cell-free preparation according to any one of claims 1–7 or the pharmaceutical composition according to any one of claims 14–16 in the manufacture of a medicament for treating a condition which involves fibrosis.

24. A non-therapeutic method for promoting one or more of the following effects: activation of keratinocytes, activation of fibroblasts, induction of mesenchymal stem cells, induction

of endogenous production of collagen I, collagen III, collagen IV, collagen VIII, elastin, EGF and/or MMP-1, the method comprising administration of the cell-free preparation according to any one of claims 1–7 or the cosmetic composition according to any one of claims 14–16 to an area of a human body in which one or more of said effects are to be promoted.

25. Use of the cell-free preparation according to any one of claims 1–7 for the manufacture of a cosmetic composition for the non-therapeutic treatment of skin.